Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel as neoadjuvant therapy for biliary tract cancer
ChiCTR2200066622Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital Airport Hospital
- Start
- Dec 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in biliary cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital Airport Hospital. Primary endpoints: Completion of all preoperative and operative therapy rate and Incidence of adverse events. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2200066622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066622.